0216/26SCR018-12/R4RGB
Media Highlights
From the 2025 ASH Annual Meeting
1
Media Outlet Article / Coverage
HealthTree TERN-701: A Promising New Therapy for #CML Patients
OncLive Experts Spotlight ASH 2025 Data Poised to Change Treatment
Paradigms in AML, MZL, and Myeloma
OncLive ASH 2025 Updates Signal Expanding Applications for
Immunotherapy and T-Cell Therapies Across Leukemia and
Lymphoma
Oncology Learning Network Novel Allosteric BCR::ABL1 Inhibitor TERN-701 Demonstrates
Encouraging Efficacy for Chronic Myeloid Leukemia: CARDINAL
Study
David Andorsky, MD
SCRI at Rocky Mountain Cancer Centers I The US Oncology Network
Media Outlet Article / Coverage
eCancer Longer Follow-Up Shows Promising PFS + MRD Negativity for
Mosunetuzumab Use in Untreated High Tumour Burden Follicular
Lymphoma
MedPage Today Bispecific Antibody Effective in Untreated Follicular Lymphoma
OncLive Frontline Treatment Discontinuation Is Higher in the Real World
vs Clinical Trials in CLL/SLL
Oncology Learning Network Subcutaneous Mosunetuzumab Demonstrates Deep, Early
Responses for Treatment-Naïve Follicular Lymphoma: Phase 2
MorningSun Trial
Oncology News Central Bispecific Administered in Outpatient Setting Shows Strong
Benefit in Follicular Lymphoma Trial
VJHemOnc ASH 2025 | ALPHA3 Study: First-line Cema-cel Consolidation for
MRD-positive LBCL After Standard Therapy
VJHemOnc ASH 2025 | MorningSun: Subcutaneous Mosunetuzumab in
Patients with Previously Untreated HTB Follicular Lymphoma
John Burke, MD
SCRI at Rocky Mountain Cancer Centers I The US Oncology Network
